Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

NCT06009627 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

119

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: dalpiciclib、Exemestane、Gosserine
DRUG: Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection

Sponsor

Tianjin Medical University Cancer Institute and Hospital